AI assistant
Aptevo Therapeutics Inc. — Director's Dealing 2022
Jun 3, 2022
35422_dirs_2022-06-03_a5a30aa5-0ad2-40a6-851c-301f4cf1402b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2016-08-03
Reporting Person: Niederhuber John (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-06-14 | Common Stock | P | 714 | $0.91 | Acquired | 1516 | Direct |
| 2022-06-01 | Common Stock | M | 298 | — | Acquired | 1814 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-01 | Restricted Stock Unit | $ | M | 298 | Disposed | Common Stock (298) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 802 | Direct |
Footnotes
F1: Shares received in a pro rata distribution by Emergent BioSolutions Inc. ("Emergent") as a result of the spin-off of the Issuer from Emergent, effective August 1, 2016, and adjusted to reflect a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020.
F2: Reflects a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020.
F3: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F4: On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022.